

Synthetic biology in mammalian cells: next generation research tools and therapeutics

Florian Lienert¹, Jason J. Lohmueller^{1,2}, Abhishek Garg¹ and Pamela A. Silver¹

Abstract | Recent progress in DNA manipulation and gene circuit engineering has greatly improved our ability to programme and probe mammalian cell behaviour. These advances have led to a new generation of synthetic biology research tools and potential therapeutic applications. Programmable DNA-binding domains and RNA regulators are leading to unprecedented control of gene expression and elucidation of gene function. Rebuilding complex biological circuits such as T cell receptor signalling in isolation from their natural context has deepened our understanding of network motifs and signalling pathways. Synthetic biology is also leading to innovative therapeutic interventions based on cell-based therapies, protein drugs, vaccines and gene therapies.

Digital logic gates

Idealized or physical devices that implement Boolean logic (such as AND, OR or NOT) on one or more inputs to produce a single output.

The field of synthetic biology seeks to make biology more efficient, reliable and predictable to engineer and in doing so to increase the scope of possible biological functions for therapeutic and research applications. Synthetic biologists rewire biological systems by modifying and recombining existing genetic elements and creating entirely new genetic parts. This approach has become possible owing to the increasing number of available genetic building blocks and a greater understanding of biomolecular modules ranging from DNA regulatory sequences to protein interaction networks and how to recombine them. The synthetic biology approach also benefits from advances in mathematical modelling and principles that have been developed in engineering disciplines¹. Such principles include the standardization of genetic modules, such as promoters or transcriptional terminator regions, and the concept of abstraction; that is, breaking down biological systems into component parts and collections of parts into devices^{2,3}.

Early synthetic biology studies focused on engineering circuits in bacterial hosts. The first systems built were inspired by electronics and included the construction of genetic switches⁴, oscillators⁵ and digital logic gates⁶. These synthetic networks showed that engineering-based methods could be used to programme computational behaviour into cells. They also helped to elucidate how naturally occurring gene networks can generate dynamic output behaviours such as oscillations or memory of transient stimuli.

Engineering of unicellular organisms has led to interesting practical applications in biosensing, therapeutics and the production of biofuels and pharmaceuticals⁷. Although in the beginning the field of mammalian synthetic biology merely mimicked and lagged behind this early bacterial work, it is now rapidly advancing owing to major developments in manipulating mammalian genomes and in methods for cloning large DNA circuits (BOX 1).

In this Review, we focus on advances in engineering synthetic circuits in mammalian cells and how they are both improving our understanding of cellular processes and stimulating the development of novel therapeutic approaches. We first describe the molecular tools and basic circuits that have been developed for engineering mammalian cells, highlighting major advances such as programmable transcription factors, as well as RNA and protein signalling devices. We then discuss how these tools are being used to study gene regulatory mechanisms, gene networks and signalling pathways. We also review applications of synthetic biology in the delivery of therapeutic agents and in the development of novel therapeutics such as chimeric antigen receptor (CAR)-modified T cells, and RNA- and cell-based vaccines. Throughout, we discuss key developments, but also highlight some genetic engineering advances that are not traditionally attributed to synthetic biology studies. Finally, we conclude by describing major technical hurdles and discuss what the future may hold for mammalian synthetic biology.

¹Department of Systems Biology, Harvard Medical School, Boston, Massachusetts 02115, USA.

²Present address: Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, USA.

Correspondence to P.A.S. e-mail: pamela_silver@hms.harvard.edu


doi:10.1038/nrm3738

Published online
17 January 2014


Box 1 | Constructing large DNA circuits

The efficiency and ease of construction of multipart DNA constructs, one of the core technologies that defines the success of synthetic biology, has improved immensely over the past decade. On one hand, this has been spurred by an exponential increase in the efficiency of DNA sequencing and short oligonucleotide synthesis¹⁴². On the other hand, newly developed methods have simplified the assembly of synthesized or pre-existing small DNA parts into large circuits. By circumventing the use of restriction endonucleases, a single-step isothermal *in vitro* recombination reaction has revolutionized the way researchers manipulate and join DNA molecules¹⁴³ (see the figure, part a). In an isothermal cloning reaction, pieces of DNA that share terminal sequence overlaps (shown in dark blue) of 20–40 base pairs in length are assembled at a constant temperature of 50 °C using three different enzymes. In the first step, T5 exonuclease removes nucleotides from the 5' ends of double-stranded DNA and generates single-strand DNA overhangs that can anneal to DNA molecules with complementary terminal sequences. In the second step, Phusion DNA polymerase fills the gaps, and Taq DNA ligase seals the nicks. T5 exonuclease is heat-labile and gradually loses its activity during the incubation at 50 °C, therefore only short overhangs of 15–20 bp are formed in the first step. Recently developed plasmid systems rely on the isothermal assembly method for the rapid and modular construction of large mammalian genetic circuits starting from a library of small sub-parts^{144,145} (see the figure, part b). These methods make use of unique nucleotide sequences (UNSeqs) that flank the library parts and facilitate isothermal assembly. Of note, one of these cloning methods has been used for the integration of large genetic circuits into single genomic sites⁴³.

a Isothermal assembly



b Modular assembly of large circuits



Tools and basic circuits

Synthetic biology is built around the concept of engineering biomolecular tools on the basis of genetic modules from different organisms and combining them into circuits to impart novel biological functionalities to host organisms. We provide an overview of these tools and discuss their applications in engineering synthetic networks.

Tools for transcriptional control. Transcription factor circuits make up the largest number of mammalian synthetic circuits to date, in part because they are intuitive to design and implement. Transcription factors consist of DNA-binding domains and transcriptional activation or repression domains for positive and negative regulation of target genes, respectively (FIG. 1a). Transcription factors bind to well-defined DNA sequences that can be used to engineer synthetic promoters^{8,9}. The first generation of synthetic gene circuits was based on

naturally existing transcription factors, such as LacI, TetR and GAL4, and synthetic promoters that contain corresponding transcription factor-binding sequences. The bacterial transcription factors LacI and TetR offer the advantage that small molecules such as isopropyl- β -D-thiogalactopyranoside (IPTG) and doxycycline can regulate their DNA-binding activity, thereby providing the ability to induce target genes at a range of expression levels^{8,9}.

Although these natural transcription factors continue to be used in specific applications, they are increasingly being replaced by programmable transcription factors such as zinc-finger-containing factors, transcription activator-like effectors (TALEs) and clustered regularly interspaced short palindromic repeats (CRISPR)-based regulators, each of which can be engineered to bind to desired DNA sequences. All of these factors are highly customizable; however, each class of transcription factor comes with advantages and trade-offs and is ideally suited

to different applications (Supplementary information S1 (table)). The design of zinc-fingers does not follow a simple code, and *in vitro* selection assays are often part of their design pipeline¹⁰. In comparison, TALEs are more straightforward to design than zinc-fingers. The DNA-binding domains of TALEs are composed of repeated domains of 34–35 amino acids, each of which recognizes and binds to a single DNA base pair with high specificity, the binding code for which was recently discovered^{11,12}. By stringing together the DNA-binding repeat domains with known specificities, TALEs can be designed to bind 7–34 bp-long DNA sequences^{13,14}. Although TALEs often display off-target binding to DNA sequences with up to 3 mismatches in the target DNA sequence, computational algorithms have been designed to address this nonspecificity^{12,14}. TALEs are large proteins with highly repetitive sequences in the DNA-binding domain, which poses challenges to cloning and delivery into host genomes. However, strategies for the efficient generation of large libraries of TALEs^{15–17} and for their viral delivery into host cells have been recently developed¹⁸.

The newest class of artificial transcription factors, CRISPR-based regulators, is based on Cas9, a protein from the bacterial CRISPR system that can bind to DNA by using a short guide RNA that is complementary to desired target DNA sequences. As a first application in mammalian cells, the endonuclease activity of Cas9 was used to generate double-strand breaks at genomic sites to induce gene mutations or homologous recombination^{19–22}. It has also been shown recently that catalytically inactive Cas9, lacking endonuclease activity, retains its DNA-binding capability and can interfere with transcriptional elongation²³. The efficiency of this repressor system can be improved by fusing the KRAB (Krüppel associated box) repressor domain to Cas9 (REF. 24). Similarly, by fusing the VP64 transcriptional activation domain to Cas9, the CRISPR system can act as a transcriptional activator^{25–27}. The ability to specify a target using an RNA molecule rather than a protein domain makes CRISPR transcription factors versatile and facilitates the generation of large libraries of these transcription factors.

Circuits based on synthetic transcription factors can be engineered to interact with endogenous signalling networks through native promoter elements, transcription factors, microRNAs (miRNAs), small molecules, proteases and cell surface receptor ligands^{28–30}. To recapitulate the expression and regulation of an endogenous gene, the promoter sequence of the endogenous gene can be fused upstream of a synthetic transcription factor coding sequence to drive its expression. Alternatively, in applications in which the synthetic circuit should sense the expression of specific endogenous transcription factors as input signals, synthetic promoter elements can be designed to harbour multiple copies of the binding sites of the transcription factor³¹. Synthetic transcription factors have also been engineered to sense metabolites and small molecules, including IPTG, doxycycline, 4-hydroxytamoxifen (4HT), uric acid, rapamycin, macrolides and streptogramin^{30,32–35}. Recently, TALEs have been designed to respond to the activation of hypoxia-inducible factor 1 α (HIF1 α), an endogenous transcription factor that

is expressed upon induction of hypoxia signalling³⁰. Physical signals such as light can also be used as input signals for transcriptional circuits, whereby light triggers the assembly of transcription factor protein fragments into a functional transcription factor³⁶. A recent study described a light-inducible TALE system, consisting of a TALE DNA-binding domain fused to the light-sensitive cryptochrome protein CRY2 and the transcriptional activator VP64 fused to CIB1 (Ca²⁺- and integrin-binding protein 1)³⁷. Illumination with blue light triggers CIB1 recruitment to CRY2 and induces VP64-mediated transcription at the site of TALE binding. The authors demonstrated that this system can be used for optogenetic modulation of endogenous transcription in the mouse brain³⁷. Similar modulation of gene expression in mammalian cells in the presence of visible light background can be achieved using ultraviolet B light-mediated protein–protein interaction systems^{38,39}.

Synthetic transcription factors and promoter elements have been used to engineer complex circuits such as networks that perform logic computation^{40–43}, feedback loops to make devices that can confer a long-lasting memory in response to a transient stimulus⁴⁴ and genetic switches for tight control of gene expression^{14,32,40}. Transcription factor-based circuits have also been built that specifically respond to intermediate levels of input, or generate time-delayed or oscillatory transcriptional output^{45,46}. Early examples of these gene circuits have used prokaryotic-based transcription factors, whereas newer synthetic transcription factors are aiming for higher scalability using programmable factors. Although many of these gene circuits were demonstrated as proof-of-concept systems, these circuits are now advancing to the stage at which they can be used as tools to modulate gene activities and cell behaviours as discussed in the applications sections.

Tools for RNA control. Although the earliest synthetic systems were largely transcription factor-based, RNA regulators are having an ever-increasing role in mammalian synthetic biology⁴⁷. RNA-based parts and regulatory mechanisms for use in mammalian cells have been engineered to respond to several different types of molecular inputs, including small molecules, metabolites and proteins⁴⁷ (FIG. 1b). These systems use aptamers, which are structured RNAs that can bind to small molecules and proteins and in response regulate the activity of other RNAs effectors on the same molecule or in *trans*. One commonly used type of RNA effector is a self-cleaving ribozyme that can degrade the RNA it resides in upon binding of a protein or small molecule to the aptamer⁴⁸. In other applications, aptamers have also been placed within introns, where they can change the splicing pattern of the mRNA in response to protein binding⁴⁹. In a more recent example, aptamers that sense the presence of specific proteins were placed in the 5' untranslated region (UTR) of transcripts, resulting in translational inhibition of these transcripts in the presence of the protein inputs⁴². Endogenous miRNAs can also be sensed by placing complementary target sequences in the 3' UTR of transcripts that code for output proteins or transcription

Optogenetic

The combination of genetics and optics to control light-sensitive proteins within specific cells.




Figure 1 | Tools used in mammalian synthetic biology. **a** | Tools for transcriptional control. DNA-binding domains from transcription factors (TFs) such as LacI, TetR or GAL4 are fused to protein domains that activate or repress transcription in mammalian cells^{8,9}. These artificial transcription factors regulate genes that contain their target-binding sites. Synthetic transcription factors based on zinc-fingers (ZFs)¹⁰, transcription activator-like effectors (TALEs)^{13,14} and clustered regularly interspaced short palindromic repeats (CRISPR)^{23–27} can be used to target any endogenous genomic region. **b** | Tools for RNA control. Aptamers can bind to proteins or small molecules. Addition of a protein-binding aptamer to an intron has been used to control the exclusion of an alternatively spliced exon (Ex2)⁴⁹. When combined with ribozymes, aptamers can degrade the RNAs in which they reside⁴⁷. Similarly, aptamers placed in 5' untranslated regions (UTRs) can regulate translation⁴². mRNA translation can also be controlled by placing combinations of sequences complementary to endogenous microRNAs (miRNAs) in the mRNA 3' UTR²⁹. **c** | Tools for protein turnover regulation. Ligand-induced protein degradation has been achieved by fusing a degradation recognition site (degron) to the target protein. In the presence of a ligand, the degron is bound by an E3 ubiquitin ligase complex⁵⁴. Alternatively, a ligand-induced degradation (LID) domain can be fused to the protein of interest. The LID domain mediates ligand-dependent degradation⁵⁵. This approach can also stabilize the target protein, by using a modified degradation domain (DD), the activity of which is blocked by a ligand⁵⁶. **d** | Tools for signalling pathway engineering. Rerouting the signalling of cell surface receptors can be achieved by engineering their ligand specificity⁵⁸. Intracellular receptor

domains have been modified by fusing the intracellular receptor domains with a tobacco etch virus (TEV) protease cleavage peptide followed by an artificial transcription factor^{59,60}. In the shown example, the TEV peptide was fused to a SRC-homology 2 (SH2) protein signalling domain, which leads to its recruitment to the receptor upon activation and subsequent release of the transcription factor⁶⁰. Chimeric antigen receptors (CARs) are synthetic T cell receptors that enable the retargeting of T cell activity towards cells with the targeted surface antigen¹⁰⁷. Rerouting of intracellular signalling proteins has been achieved by reengineering their interaction domain such that it only recognizes an engineered binding partner but not the natural occurring counterpart⁶³. Alternatively, proteins have been brought into close proximity to each other by fusing them to protein dimerization domains, which are either constitutively active or induced by small molecules or light^{37,64,91,146}. Inteins and split (trans-acting) inteins are proteins that can self-excite and ligate the peptides fused to them. **e** | Tools for genome engineering. Recombinases catalyse the recombination of a pair of short target sequences (triangles), which are pre-integrated into the genome. Depending on the target sequence configuration, DNA elements can be inserted, deleted, inverted or replaced⁷⁰. Nucleases fused to DNA-binding factors such as zinc-finger nucleases (ZFNs)^{74,75} or TALE nucleases (TALENs)⁷⁶, as well as CRISPR-based systems^{19–21} have been used to induce a double-strand break at any given DNA locus. Upon double-strand break formation, the non-homologous end joining (NHEJ) or homologous recombination pathway induces a mutation or insertion of sequence fragments, respectively. GPCR, G protein-coupled receptor; ORF, open reading frame; RTK, receptor Tyr kinase.

factor regulators²⁹. In the presence of the miRNA, the mRNA transcript is either degraded or translationally repressed by RNAi activity. Circuits composed of up to six different miRNA inputs have been demonstrated to classify cell types on the basis of miRNA expression patterns²⁹. Furthermore, siRNA- and miRNA-based regulators have also been shown as viable options for Boolean logic computing frameworks⁵⁰.

RNA-based parts and devices hold many advantages but also trade-offs compared with other types of regulators. RNA-based systems are relatively fast-acting, as they do not require translation. They are also well-suited for sensing certain types of molecules such as miRNAs and further benefit from directed molecular evolution methods for quick screening for RNA aptamers with new specified binding properties⁵¹. Furthermore, RNA-targeted systems are very effective when combined with transcriptional regulation. Inhibitory RNA combined with transcriptional repressors can lead to near complete repression of gene activity^{14,32}. However, although miRNA regulation is very robust, some of the other RNA-based sensors can be less sensitive as compared to transcription factor-based systems⁴⁹.

Tools for protein turnover regulation. Altering protein stability is a powerful way to rapidly and post-translationally control protein activity. Protein stability depends on several factors such as the length of the peptide sequence and the occurrence of specific amino acids that can be phosphorylated⁵². Furthermore, proteins can be actively degraded through the ubiquitylation pathway, wherein an E3 ubiquitin ligase recognizes proteins that harbour a specific domain and catalyses the transfer of ubiquitin to this target protein, ultimately leading to its recognition and degradation by the proteasome⁵³. In some instances, target recognition by an E3 ubiquitin ligase can be regulated by a small-molecule ligand. For example, the *Arabidopsis thaliana* TRANSPORT INHIBITOR RESPONSE 1 (TIR1) protein has recently been shown to form an active E3 ubiquitin ligase complex in mammalian cells, and it binds its recognition site upon addition of auxins, which are plant hormones that control gene expression⁵⁴. This system has been used to reversibly induce degradation of a fluorescent protein that was engineered to contain a recognition site for TIR1 (REF. 54) (FIG. 1c).

An alternative method for ligand-induced protein degradation has been developed by screening variants of the FK506- and rapamycin-binding protein (FKBP) that have additional amino acid residues appended to the carboxyl terminus⁵⁵. This screen has revealed a ligand-induced degradation (LID) domain, which when fused to a protein confers stability in the absence of a ligand and causes rapid degradation in the presence of the high-affinity ligand Shield-1 (REF. 55). Conversely, a different variant of FKBP has been engineered to confer protein stability specifically in the presence of the Shield-1 ligand⁵⁶. Work in yeast has also demonstrated a novel light-reactive protein degradation domain, which opens the possibility of using light to regulate protein stability in mammalian cells⁵⁷.

Tools for signalling pathway engineering. Several synthetic signalling networks have been engineered to introduce novel control schemes or reroute information flow (FIG. 1d). Modified membrane receptors that detect unnatural small molecules represent one class of tools that can offer orthogonal external control of cellular function. For instance, directed molecular evolution has been used to change the ligand specificity of G protein coupled receptors (GPCRs)⁵⁸. Rerouting signalling output has also been accomplished by modifying the intracellular domain of receptors. In one such approach, artificial transcription factors are fused to the intracellular domain of membrane receptors to translate extracellular signals into transcriptional outputs. This mechanism has been implemented in the Notch receptor by replacing its intracellular domain with the transcriptional activator GAL-VP16, which gets cleaved upon binding to the Delta ligand⁵⁹. Similarly, the output of GPCRs has been rerouted using tobacco etch virus (TEV) protease. In this system, the intracellular domain of the GPCR has been fused to a TEV protease recognition site followed by a synthetic transcription factor. Upon GPCR activation, the small signalling transduction protein arrestin fused to TEV protease is recruited to the GPCR, which leads to the release of the artificial transcription factor⁶⁰. An analogous system has been developed for receptor Tyr kinases, in which the TEV protease is fused to a SRC-homology 2 (SH2) protein domain that is recruited to the activated receptor⁶⁰. By fusing the death effector domain FADD to SH2, receptor activation has also been rerouted to induce cell death⁶¹. Another notable example of reengineered receptors are CARs, which are synthetic T cell receptors that enable the retargeting of T cell activity towards cells with the targeted surface antigen (see the following sections for more details).

Cytosolic proteins involved in intracellular signalling consist of multiple domains that define their catalytic activity, localization and binding to scaffold proteins. Proteins with novel functionalities can be engineered by recombining these domains⁶². The engineering of such signalling networks requires modifying protein–protein interactions, which for many applications are ideally orthogonal to the protein interaction network of the host cell. One recent example of designing orthogonal signalling proteins is the engineering of the GTPase CDC42 and its activator intersectin⁶³. The engineered version of CDC42 is exclusively induced by its cognate partner, while maintaining its ability to interact with other GTPase signalling components⁶³. Alternatively, specificity and orthogonality in synthetic signalling networks can be achieved by fusing interaction domains to dimerizing proteins such as synthetic coiled-coil peptides⁶⁴.

A unique class of tools for post-translational circuit engineering are inteins, which are protein splicing domains that can self-excite and ligate attached peptides. Inteins and split (*trans*-acting) inteins that are activated in response to small molecules, light and protein inputs have been generated, enabling the post-translational control of circuits^{65–67}. There are also several systems available that use light to induce protein–protein interactions in a reversible manner. For instance, it has

Directed molecular evolution

A method that mimics the process of natural selection to evolve proteins or nucleic acids towards a user defined goal.

Orthogonal

A system is orthogonal when changes to one component do not influence the other components.

been shown that fusing the kinase CRAF (also known as RAF1) to CRY2, which dimerizes in response to blue light, allows the regulation of the kinase activity using light⁶⁸. Similarly, light-induced oligomerization of a WNT receptor domain has been used to activate the β -catenin pathway⁶⁹.

Tools for genome engineering. Site-specific recombination was among the first technologies that enabled the precise manipulation of mammalian genomes. The method relies on bacterial or fungal recombinases that catalyse the recombination of a pair of short target sequences (for example, LoxP sites in the case of Cre recombinase) that are pre-integrated into the genome around loci of interest⁷⁰ (FIG. 1e). Upon induction of the recombinase, the intervening DNA is either flipped or excised depending on the orientation of the recombinase-target sites. In mice, increased specificity of conditional gene knock-outs has been achieved through an expression cassette that is controlled by the combined activity of two different recombinases, which in turn are induced by different tissue-specific promoters⁷¹. Such an *in vivo* 'AND' gate, which induces a knock-out in response to a combination of two signals, has also been created by expressing the two fragments of a split Cre recombinase from two different tissue-specific promoters^{72,73}.

The traditional method for site-specific gene targeting in mammalian cells involves transfection of DNA containing the desired alterations together with flanking long homologous DNA strands and selection of rare modified cells. However, this technique is highly inefficient. The development of programmable DNA nucleases to introduce site-specific DNA breaks, a potent inducer of localized homologous recombination, has greatly improved the process. In the case of zinc-finger nucleases (ZFNs)^{74,75} and TALE nucleases (TALENs)⁷⁶, each of a pair of engineered DNA-binding proteins is fused to a *FokI* nuclease domain (FIG. 1d). The fusion proteins are engineered to bind in close proximity on DNA, leading to the dimerization of *FokI* and the induction of a double-strand break at the target site. The recently developed CRISPR system relies on a DNA endonuclease that is targeted to DNA by a short RNA rather than a protein domain, which makes this method very versatile^{19–21}. Thus far, editing of the mammalian genome by CRISPR seems to be very efficient and enables multiple alleles to be mutated in parallel²². However, high levels of off-target cleavage by CRISPR–Cas nucleases have been observed and still need to be addressed⁷⁷.

Multiplexed genome engineering (MAGE), which relies on oligonucleotide-mediated recombineering, is an alternative method for editing multiple genetic loci in parallel⁷⁸. Demonstrated to be useful in bacteria⁷⁸, the adaptation of this method to mammalian cells is still under way⁷⁹.

The tools described in this section enable the manipulation of one or more genetic loci. Moreover, there have also been efforts towards synthesizing whole genomes *de novo*. Synthesis of a mitochondrial genome has been reported in 2010 (REF. 80), and *de novo* synthesis of a yeast genome is currently being developed⁸¹.

Synthetic biology in basic research

The past decade has seen enormous advances in mapping the genome and proteome in different biological systems, including mammalian cells. Although this has led to an increasingly comprehensive picture of gene and protein networks, there is still a need for deeper mechanistic understanding of these systems. Synthetic biology approaches offer potential insight into the logic of cellular systems at different levels by rebuilding and studying them in a context isolated from their high degree of natural interconnectivity.

Studying chromatin and gene regulation. Gene activity in eukaryotes is regulated by a complex interplay between *cis*- and *trans*-acting DNA elements such as promoters and enhancers. Novel high-throughput methods for testing the activity of synthetic DNA sequences have helped to understand the architecture of these gene regulatory regions. For instance, a library of tandem repeats of all possible 10-mer DNA sequences has been cloned upstream of GFP under the control of a minimal promoter and tested for its activity after retroviral-mediated transfection into human cell lines⁸². This approach led to the identification of a novel strong synthetic promoter and revealed transcription factor-binding motifs that can induce high levels of transcription⁸². The efficiency of testing such libraries has been improved by 'bar-coding' promoter variants with short DNA sequences and measuring their activity by high-throughput RNA sequencing⁸³ (FIG. 2A). This method, termed massively parallel reporter assay, has recently been used to study a large number of variants of endogenous enhancers as well as combinations of conserved regulatory motifs found in enhancers^{84–87}.

In addition to transcription factor occupancy of regulatory DNA elements, eukaryotic gene expression is also influenced by changes to chromatin through DNA methylation, nucleosome positioning and post-translational modifications of histones. In order to change the chromatin environment at specific genomic locations, enzymes that catalyse the addition or removal of chromatin marks have been fused to programmable transcription factors that can be directed to any sequence of interest. This approach was first demonstrated by the fusion of a zinc-finger transcription factor with a DNA methyltransferase⁸⁸. Recently, the same principle has been adapted to TALEs^{37,89,90}. In one such application, directing the activity of ten-eleven translocation 1 (TET1), an enzyme involved in the demethylation of DNA, to gene promoters has revealed methylation sites that are crucially involved in gene repression⁸⁹. In another similar application, site-specific targeting of the histone demethylase Lys-specific demethylase 1 (LSD1) has been used to study the interplay between histone marks found at enhancers and nearby genes⁹⁰ (FIG. 2Ba). Small molecule-induced dimerization has also been used to recruit chromatin-modifying enzymes in a rapid and reversible manner⁹¹. It has been shown that transient induction of a repressive histone modification at the *Oct4* (also known as *Pou5f1*) gene leads to its heritable transmission through multiple cell

Recombineering
Genetic engineering that is based on homologous recombination systems.




Figure 2 | Studying chromatin and gene regulation. **A** | Testing libraries of gene regulatory regions. A large number of synthetic variants of endogenous promoters or sequences containing combinations of transcription factor (TF)-binding motifs are cloned upstream of a minimal promoter driving a reporter gene. The constructs also contain a short variable nucleotide sequence that serves as a 'barcode' and can be associated with the inserted promoter sequence by high-throughput sequences of the library. The library is injected into mice or transfected into cultured cells, and its activity is measured by RNA sequencing. **B** | Recruitment of chromatin-modifying enzymes by zinc-fingers (ZFs) or transcription activator-like effectors (TALEs). Site-specific targeting of the histone demethylase LSD1 has been used to study the interplay between histone marks found at enhancers and nearby genes⁹⁰ (**Ba**). Reversible recruitment of chromatin-modifying enzymes. Rapamycin-inducible dimerization with the transcription factor GAL4 has been used to recruit heterochromatin-binding protein 1 α (HP1 α), a component of repressive chromatin, to GAL4-binding sites integrated at the *Oct4* promoter⁹¹. The histone H3 Lys9 methylation mark, indirectly induced by HP1 α , has been shown to be epigenetically transmitted after washout of rapamycin and loss of HP1 α binding (**Bb**). Light-inducible transcriptional effectors (LITEs). Light stimulation induces dimerization of the cryptochrome protein CRY2 and CIB1 (Ca²⁺- and integrin-binding protein 1), leading to the recruitment of a chromatin-modifying enzyme (shown in light blue) to the target promoter³⁷ (**Bc**).

generations⁹¹ (FIG. 2Bb). Transient induction can also be triggered by light, as has been recently demonstrated by a new system termed light-inducible transcriptional effectors (LITEs) for reversible, TALE-guided targeting of chromatin-modifying enzymes³⁷ (FIG. 2Bc).

Studying gene networks. Genes and their regulators form highly interconnected networks, the topology of which can be inferred (or reverse-engineered) from perturbation and gene expression data. In order to benchmark reverse-engineering algorithms, small synthetic gene networks have been engineered within the natural cellular environment of yeast and human cells^{92,93} (FIG. 3a).

Gene regulatory networks from bacteria to humans are characterized by the occurrence of several over-represented network motifs^{94,95}. Synthetic gene circuits have enabled the study of these network motifs in isolation from their natural interconnections (FIG. 3b). The positive feedback loop, in which transcription of a gene is activated by its own output, is one common motif^{94,95}. By rebuilding this motif as a synthetic gene circuit, it has been shown that it generates hysteresis, meaning that the induction of the repressed state requires a reduction of the input beyond the amount that is

necessary for activation⁹⁶. Another common motif is a type I incoherent feedforward loop, which consists of an input that activates both an output and an auxiliary gene, which in turn represses the output (FIG. 3b). A circuit with this regulatory motif has been demonstrated to adapt in response to the amount of genetic template and was therefore suggested to have a role in gene dosage compensation⁹⁷. Synthetic circuits have also been used to generate oscillatory gene expression as found for genes controlled by the circadian clock. A genetic circuit consisting of a positive feedback loop and a time-delayed negative feedback loop has produced robust oscillations and revealed system parameters for tuning the oscillatory behaviour in mammalian cells⁴⁶. Of note, combinations of positive and negative feedback loops have also been found to underlie natural oscillatory networks, such as the cell cycle in *Xenopus laevis* embryos⁹⁸. For more examples of how synthetic gene circuits have been used to study their natural counterparts, we refer the reader to a recent review⁹⁹.

Studying cell signalling. Rebuilding artificial signalling networks and studying them in an exogenous context obviates the challenges of interconnectivity that involve

Gene dosage compensation
Mechanisms that dampen fluctuations in gene expression levels in response to changes in gene copy numbers.




Figure 3 | Studying gene and signalling networks. **a** | Schematic of reverse engineering with synthetic circuits. A benchmark gene circuit is integrated into a mammalian cell line. Different reverse engineering algorithms are used to generate a network model from perturbation and gene expression analysis. The quality of reverse engineering algorithms is assessed and improved by comparing the resulting models to the actual circuit architecture in an iterative cycle⁹³. **b** | Studying gene network architectures. Synthetic gene circuits enable the study of network modules in isolation from their natural context in which they may be interconnected with other endogenous signalling pathways (shown in blue). The schematic shows the design of a type I incoherent feedforward loop circuit, consisting of an input (shown in brown) that activates both an output (shown in red) and an auxiliary gene (shown in green) which represses the output⁹⁷. **c** | Studying signalling pathways by heterologous reconstitution. A mammalian MAPK pathway, consisting of an estradiol-inducible RAF1 protein that activates MEK1, which in turn activates ERK2, has been expressed in yeast. Increased concentration of each protein at each step of the cascade has been shown to augment the degree of input ultrasensitivity¹⁰¹. ER, oestrogen receptor.

endogenous competing signalling networks and enables the essential components of a signalling pathway to be defined. Following such an approach, the genes encoding proteins involved in the T cell receptor (TCR) signalling pathway, which are normally only active in T lymphocytes, were expressed in a non-immune cell¹⁰⁰. With a set of more than 10 heterologously expressed proteins, the authors of this study recapitulated TCR signalling and tested competing biophysical models of TCR activation.

Mammalian signalling pathways have also been studied by heterologous reconstitution in different organisms. For example, a MAPK activation cascade based on the mammalian ERK1 and ERK2 pathway and including RAF1, MEK1 and ERK2 has been shown to be functional and well insulated (that is, not interfering with other endogenous pathways) when expressed in yeast¹⁰¹. Perturbation of the system in yeast has revealed insights into natural MAPK cascades, which, in certain contexts, show a graded response whereas, in others, show a switch-like (ultrasensitive) activation. Specifically, it has been demonstrated that increasing the concentration of each sequential protein at each step of the cascade increases the degree of input ultrasensitivity (an increase in the Hill coefficient) and reduces the activation threshold (FIG. 3c).

Synthetic biology in therapy

Synthetic biology aims to develop new approaches for therapeutic interventions through enhanced efficiency, predictability and safety of engineered systems, as well as by expanding the possibilities for regulating biological systems. We provide an overview of novel therapeutic strategies and outline where synthetic biology approaches are helping to improve existing treatment options.

Gene therapy. After suffering a number of setbacks, the field of gene therapy has recently regained traction by the approval of the first commercial gene therapy treatment, Glybera (Uniqure), for lipoprotein lipase deficiency¹⁰². For this and many other current therapies, genes are packaged within viruses, which can be locally administered to the tissue of interest. However, higher degrees of specificity are needed and targeting the right cell types can be critical. Gene therapies are beginning to benefit from synthetic biology approaches aimed at both improving the specificity of the gene delivery and the specificity of the expression of therapeutic genes. For instance, in a recent study, a large library of adeno-associated virus variants was generated and *in vivo*-directed evolution was used to identify a virus that can target the cells of the outer retina¹⁰³. Cell type-specific activity could also be achieved by expressing therapeutic genes from promoter elements that are active only in certain cell types³¹.

Gene therapy has also been performed in combination with autologous cell transplantation, in which stem cells from a patient are removed, treated and later reintroduced in the same individual. Gene replacement therapy in autologous haematopoietic stem cells has recently shown promising outcomes for the treatment of inherited diseases^{104,105}. This method of delivery has also been explored for direct manipulation of endogenous genes to either correct or induce mutations. For instance, there are ongoing clinical trials for HIV therapeutics that are based on targeted gene disruption in T cells. In this case, a ZFN is used to mutate the chemokine receptor 5 (CCR5) gene in autologous CD4⁺ T cells, which then become resistant to HIV and outlive HIV-infected cells¹⁰⁶. Such therapeutic approaches based on genome editing are expected to benefit from tools recently developed in the synthetic biology field, such as TALENs and CRISPR.




Figure 4 | Chimeric antigen receptor therapy. **A** | The classic chimeric antigen receptor (CAR) therapy (CAR-T) approach. T cells are engineered *ex vivo* to express a CAR and then transferred into the original donor patient, where they destroy cells that display the target antigen. **B** | AND gate CAR therapy. T cells are engineered to express two CARs, one with a weakened single chain variable fragment (scFv) domain and one that contains co-stimulatory domains in its intracellular domain. These engineered T cells have been shown to preferentially target cells that display two antigens together¹⁰⁹. **C** | Gene circuits for controlling CAR therapy activity. A RNA device enables the control of T cell proliferation. The device stabilizes the expression of secreted interleukin-15 (IL-15), a proliferation-inducing cytokine, in the presence of the small-molecule drug Theophylline¹¹¹ (**Ca**). The amplitude limiter device uses a promoter that is activated upon T cell signalling and induces the expression of the bacterial virulence protein OspF, which in turn irreversibly inactivates T cell signalling. This negative feedback loop has been shown to dampen the amplitude of T cell activation¹¹² (**Cb**). The pause switch device consists of a construct that induces OspF expression and thereby inhibits T cell activation in response to doxycycline¹¹² (**Cc**). LAT, linker activator for T cells; TCR, T cell receptor; ZAP70, ζ -chain-associated protein kinase 70.

Chimeric antigen receptor-based T cell therapy. CARs are synthetic T cell receptors that enable the retargeting of T cell activity towards cells with the targeted surface antigen¹⁰⁷. In this approach, T cells of a patient are engineered *ex vivo* to express the CAR and then adoptively transferred into the patient, thus killing targeted cells. Recently, CAR-based immunotherapies have been successful in targeting cancer types for which no other appropriate treatment was available¹⁰⁸. CARs are modular fusion proteins that consist of cytoplasmic signalling domains from the T cell receptor and T cell co-receptor, a *trans*-membrane region, an extracellular linker and an antigen-targeting element, which is most often a single chain variable fragment (scFv) antibody. In all CAR-based therapies that are currently in the clinic, cancer cells are targeted on the basis of single cancer-specific antigens and thus can essentially kill every cell that contains the targeted antigen (FIG. 4A). Although showing very promising results, even in current therapies many

‘on-target off-tumour’ effects have been observed that can lead to lethal toxicity¹⁰⁸. Thus, a current focus is engineering greater specificity to CAR-modified T cells.

One recent approach to increase specificity involved the creation of a CAR-based AND logic gate that used novel CARs to target and kill cells that express two antigens but not the cells that displayed only one or none of the antigens^{109,110} (FIG. 4B). A different system focused on controlling T cell proliferation and comprised an RNA control device that allowed stabilization of interleukin-15 (IL-15; a proliferation-inducing cytokine) only in the presence of a small-molecule drug¹¹¹ (FIG. 4Ca). In yet another recent paper, kinase inhibitors from human pathogens have been used to rewire the TCR signalling pathway to produce novel behaviours in T cell signalling, including a delayed TCR signalling ‘pause switch’ and feedback modulators in order to tune the amplitude of the T cell signalling response¹¹² (FIG. 4Cb,Cc).




Figure 5 | Prosthetic networks and protein-based therapies. **a** | Prosthetic networks. Implantation of genetically engineered cells that are encapsulated in a semi-permeable membrane enables diffusion of small molecules and proteins and at the same time acts as a barrier to the immune system. Cells implemented in such systems have been engineered to release small effector proteins (the 'output') in response to specific molecular inputs (shown in blue and orange)^{33,35,113,115}. **b** | Protein-based therapies. When fused to antibodies or receptor ligands, therapeutic proteins such as cytokines can be targeted to cells that express the corresponding antigen or receptor, respectively¹¹⁶. In the case of chimeric activators, the therapeutic protein has been mutated to have low affinity for its receptor, resulting in a reduced response in cells that only bind the therapeutic protein but are not bound by the targeting element^{118,119}. Fusion to proteins that carry a high positive surface charge has been shown to facilitate intracellular delivery of proteins^{128–130}. GLP1, glucagon-like peptide 1.

Prosthetic networks. Implantation of genetically engineered encapsulated cells is currently being explored as a method for delivering complex gene control circuits¹¹³. Encapsulating cells in a biocompatible and semi-permeable material such as alginate enables diffusion of small molecules and proteins yet prevents immune reactivity and potential release of genetic information (FIG. 5a). In 1980, encapsulated pancreatic islet cells have been used to sense blood glucose levels and secrete insulin in a rat model of diabetes¹¹⁴. Recently, this encapsulation method has been extended to xenogeneic cells, which are engineered to harbour 'prosthetic networks', which are synthetic circuits that sense disease-relevant metabolites and can coordinate diagnostic, preventive and therapeutic responses^{35,113}. In one study, encapsulated mammalian cells were engineered to release uric acid eliminating urate oxidase in response to high levels of uric acid, thus controlling hyperuricemia³³. In another instance, encapsulated cells contained a synthetic signalling cascade for light-inducible transgene expression¹¹⁵. Upon transdermal illumination, the implanted cells released glucagon-like peptide 1 (GLP1), which regulated glucose homeostasis¹¹⁵. Finally, a combined drug- and gene-based therapy has recently been described, consisting of encapsulated cells engineered to release the metabolically active

peptides GLP1 and leptin in response to administration of the antihypertensive drug guanabenz³⁵.

Protein-based therapies. Protein-based therapies have various advantages over nucleic acid-based or cell-based therapies as they can be administered locally and transiently and override the safety concerns associated with genomic manipulation strategies. Most protein-based drugs are naturally occurring proteins such as growth factors and antibodies that work through cell surface receptors to modulate the activity of signalling pathways. Synthetic biology aims at improving such therapeutics by testing combinations and variants of these proteins (FIG. 5b). For instance, direct fusion of antibodies with therapeutic proteins has led to enhanced targeting to cells¹¹⁶. In addition, bi-specific antibodies have enabled retargeting of T cell activities to targeted cells¹¹⁷. Another system, which is an extension of fusion proteins and is called chimeric activators enables even better cell targeting of therapeutic molecules^{118,119}. Chimeric activators comprise a targeting molecule such as an antibody or growth factor specific to target cells and an activity protein that is mutated to have low affinity for its receptor on the target cell surface. Cell surface binding of the targeting domain of chimeric activators increases the local concentration of the activity protein

Xenogeneic cells
Cells that belong to individuals of different species.

to levels high enough to activate signalling in only the target cells. Chimeric activators have been generated to target mutated versions of the therapeutic proteins interferon- α 2a (IFN α 2a) and erythropoietin (EPO) to cells with epidermal growth factor receptor (EGFR) and glycophorin, respectively^{118,119}.

Another focus has been intracellular protein delivery to mammalian cells based on liposomes^{120–122}, nanoparticles^{123–125}, fusion with receptor ligands^{126,127} and ‘supercharged’ tags, which are polypeptides with an unusually high net charge^{128,129}. In particular, fusing proteins with naturally occurring high net positively charged proteins and synthetic supercharged GFP, a GFP re-designed to have high positive surface charge, has been shown to be an effective mechanism to improve the cellular uptake of biologically active protein drugs in mouse tissues¹³⁰. Supercharged fusion proteins have also been demonstrated to improve the stability and block the aggregation of proteins¹²⁹.

Synthetic biology in vaccines. To prevent outbreaks of rapidly evolving pathogens, the swift development of a vaccine is of paramount importance. Recently, it was demonstrated that a vaccine for influenza could be completed in under a week’s time using a synthetic biology approach that involved bioinformatics, gene synthesis and a mammalian cell line production system¹³¹. Computer-aided design in combination with whole-genome synthesis has also been used to recode polio and influenza viruses to contain infrequently used codon pairs, representing a novel method for creating safe live attenuated viruses for vaccination^{132,133}. RNA-based vaccines represent another exciting area; synthetic RNA transfected into cells can produce vaccine antigens for rapid and efficient cell presentation and immunity. As the RNA does not mutate the genome, it does not have the safety concerns associated with DNA vaccines, and, although it is less stable than DNA, RNA can be produced at large scale in a timely fashion. Recently, the use of self-replicating RNA machinery has allowed long-term expression of antigens, which leads to a more stable response of RNA vaccines¹³⁴.

Vaccines are also being developed to stimulate immunity against cancers. A cancer vaccine based on dendritic cells, Provenge (Dendreon), was recently approved for use in prostate cancer, and many other therapeutic cancer vaccines are currently in clinical trials. Provenge is formulated from autologous dendritic cells of a patient loaded with prostate cancer antigen, and granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine that helps in improving dendritic cell maturation. The success rate of these cell vaccines could perhaps be further improved through genetic engineering of dendritic cells in combination with ways to overcome systemic immunosuppression¹³⁵.

Perspective

The combination of genetically engineered cells with recent developments in mimicking complex tissue structures and living organs has great potential to

advance tissue engineering. Driven by progress in microfluidics, novel microdevices are able to emulate tissue structures, their dynamic mechanical properties and their biochemical functions¹³⁶. These devices are currently built using primary or immortalized cells, and the development of genetically engineered cells offers the opportunity to create even more sophisticated organ models. Cells that contain genetic circuits for synthetic pattern formation¹³⁷ or induction of distinct cellular states^{49,138} could be used to create complex patterns of cells with different functionality. Besides offering insights into normal and diseased organ function, organ-mimicking devices are useful for preclinical drug development and toxicity screening¹³⁶. For example, engineered cells could be used to monitor cellular responses, specifically by genetic circuits that sense cellular states^{29,139} and confer memory to transient stimuli⁴⁴.

Engineered cells have also helped to advance therapeutic applications such as CAR therapies and cancer vaccines. However, mammalian system engineering still needs to overcome a number of technical hurdles, such as the scalability, orthogonality and predictability of synthetic circuit behaviours. Although programmable transcription factors and engineered protein–protein interaction domains are leading the way in addressing the problem of orthogonality, the predictability of genomically integrated DNA-based circuits still remains a cause of concern due to site- and cell type-specific effects. As one possible solution, the mammalian synthetic biology community could agree on characterizing circuits in a set of genomic loci such as safe harbour sites known to tolerate the integration of transgenes¹⁴⁰. Alternatively, one could consider expressing circuits from a human artificial chromosome, which can hold large amounts of DNA and does not integrate into the host genome. For the challenge of scalability, the key might be to use different types of regulators that act on different classes of molecules, for instance an assortment of transcriptional and post-translational regulators of RNA and proteins, as recently demonstrated for circuits that performed multi-bit (that is, the integration of multiple digital inputs) processing in mammalian cells⁴².

For therapeutic applications that are based on genetically engineered cells, the field also needs to address the issue of immunogenicity of the circuit components and cells. In this case, insights can be gained from CAR therapy technologies. For example, it has recently been shown that T cells made from induced pluripotent stem (iPS) cells can be used for CAR therapy, which offers an off-the-shelf alternative to autologous T cell isolation¹⁴¹. The authors of this study proposed that the alloreactivity of iPS cell-derived T cells could be eliminated by disrupting the endogenous TCR, whereas allorejection could be minimized by generating iPS cells from common human leukocyte antigen (HLA) haplotypes.

We anticipate that continuing progress in mammalian synthetic biology will lead to new interesting applications in basic cell biology and the development of novel therapeutics.

Alloreactivity

The immunologic reactions that occur when T cells are transplanted between two individuals of the same species.

1. Endy, D. Foundations for engineering biology. *Nature* **438**, 449–453 (2005).
2. Knight, T. DARPA BioComp Plasmid Distribution 1.00 of Standard Biobrick Components. *MIT Synthet. Biol. Work. Group Rep.* (2002).
3. Mutalik, V. K. *et al.* Precise and reliable gene expression via standard transcription and translation initiation elements. *Nature Methods* **10**, 354–360 (2013).
4. Gardner, T. S., Cantor, C. R. & Collins, J. J. Construction of a genetic toggle switch in *Escherichia coli*. *Nature* **403**, 339–342 (2000).
5. Elowitz, M. B. & Leibler, S. A synthetic oscillatory network of transcriptional regulators. *Nature* **403**, 335–338 (2000).
6. Guet, C. C., Elowitz, M. B., Hsing, W. & Leibler, S. Combinatorial synthesis of genetic networks. *Science* **296**, 1466–1470 (2002).
7. Khalil, A. S. & Collins, J. J. Synthetic biology: applications come of age. *Nature Rev. Genet.* **11**, 367–379 (2010).
8. Brown, M. *et al.* Lac repressor can regulate expression from a hybrid SV40 early promoter containing a lac operator in animal cells. *Cell* **49**, 603–612 (1987).
9. Gossen, M. & Bujard, H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. *Proc. Natl Acad. Sci. USA* **89**, 5547–5551 (1992).
10. Maeder, M. L. *et al.* Rapid “open-source” engineering of customized zinc-finger nucleases for highly efficient gene modification. *Mol. Cell* **31**, 294–301 (2008).
11. Boch, J. *et al.* Breaking the code of DNA binding specificity of TAL-type III effectors. *Science* **326**, 1509–1512 (2009).
12. Moscou, M. J. & Bogdanove, A. J. A simple cipher governs DNA recognition by TAL effectors. *Science* **326**, 1501 (2009).
- References 11 and 12 describe how the DNA-binding specificity of TALEs is determined.**
13. Morbitzer, R., Romer, P., Boch, J. & Lahaye, T. Regulation of selected genome loci using *de novo*-engineered transcription activator-like effector (TALE)-type transcription factors. *Proc. Natl Acad. Sci. USA* **107**, 21617–21622 (2010).
14. Garg, A., Lohmueller, J. J., Silver, P. A. & Armel, T. Z. Engineering synthetic TAL effectors with orthogonal target sites. *Nucleic Acids Res.* **40**, 7584–7595 (2012).
15. Reyon, D. *et al.* FLASH assembly of TALENs for high-throughput genome editing. *Nature Biotech.* **30**, 460–465 (2012).
16. Morbitzer, R., Elsaesser, J., Hausner, J. & Lahaye, T. Assembly of custom TALE-type DNA binding domains by modular cloning. *Nucleic Acids Res.* **39**, 5790–5799 (2011).
17. Schmid-Burgk, J. L. *et al.* Rapid hierarchical assembly of medium-size DNA cassettes. *Nucleic Acids Res.* **40**, e92 (2012).
18. Holkers, M. *et al.* Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. *Nucleic Acids Res.* **41**, e63 (2013).
19. Cong, L. *et al.* Multiplex genome engineering using CRISPR/Cas systems. *Science* **339**, 819–823 (2013).
20. Jinek, M. *et al.* RNA-programmed genome editing in human cells. *eLife* **2**, e00471 (2013).
21. Mali, P. *et al.* RNA-guided human genome engineering via Cas9. *Science* **339**, 823–826 (2013).
- References 19–21 describe how the bacterial CRISPR system can be used for genome engineering in human cells.**
22. Wang, H. *et al.* One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. *Cell* **153**, 910–918 (2013).
23. Qi, L. S. *et al.* Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. *Cell* **152**, 1173–1183 (2013).
24. Gilbert, L. A. *et al.* CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. *Cell* **154**, 442–451 (2013).
25. Maeder, M. L. *et al.* CRISPR RNA-guided activation of endogenous human genes. *Nature Methods* **10**, 977–979 (2013).
26. Mali, P. *et al.* CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. *Nature Biotech.* **31**, 833–838 (2013).
27. Perez-Pinera, P. *et al.* RNA-guided gene activation by CRISPR-Cas9-based transcription factors. *Nature Methods* **10**, 973–976 (2013).
28. Wehr, M. C. *et al.* Monitoring regulated protein–protein interactions using split TEV. *Nature Methods* **3**, 985–993 (2006).
29. Xie, Z., Wroblewska, L., Prochazka, L., Weiss, R. & Benenson, Y. Multi-input RNAi-based logic circuit for identification of specific cancer cells. *Science* **333**, 1307–1311 (2011).
- Reports the engineering of a circuit that integrates a combinatorial signal of six miRNAs for sensing a specific cancer cell type.**
30. Li, Y., Moore, R., Guinn, M. & Bleris, L. Transcription activator-like effector hybrids for conditional control and rewiring of chromosomal transgene expression. *Sci. Rep.* **2**, 897 (2012).
31. Whitfield, T. W. *et al.* Functional analysis of transcription factor binding sites in human promoters. *Genome Biol.* **13**, R50 (2012).
32. Deans, T. L., Cantor, C. R. & Collins, J. J. A tunable genetic switch based on RNAi and repressor proteins for regulating gene expression in mammalian cells. *Cell* **130**, 363–372 (2007).
33. Kemmer, C. *et al.* Self-sufficient control of urate homeostasis in mice by a synthetic circuit. *Nature Biotech.* **28**, 355–360 (2010).
- Reports the implantation of encapsulated cells that were engineered to release urate oxidase in response to high levels of uric acid for controlling hyperuricemia.**
34. Leisner, M., Bleris, L., Lohmueller, J., Xie, Z. & Benenson, Y. Rationally designed logic integration of regulatory signals in mammalian cells. *Nature Nanotechnol.* **5**, 666–670 (2010).
35. Ye, H. *et al.* Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome. *Proc. Natl Acad. Sci. USA* **110**, 141–146 (2013).
36. Polstein, L. R. & Gersbach, C. A. Light-inducible spatiotemporal control of gene activation by customizable zinc finger transcription factors. *J. Am. Chem. Soc.* **134**, 16480–16483 (2012).
37. Konermann, S. *et al.* Optical control of mammalian endogenous transcription and epigenetic states. *Nature* **500**, 472–476 (2013).
- Describes the development of a TALE-based, light-inducible system for controlling transcription and chromatin states in vitro and in vivo.**
38. Crefcoeur, R. P., Yin, R., Ulm, R. & Halazonetis, T. D. Ultraviolet-B-mediated induction of protein-protein interactions in mammalian cells. *Nature Commun.* **4**, 1779 (2013).
39. Muller, K. *et al.* Multi-chromatic control of mammalian gene expression and signaling. *Nucleic Acids Res.* **41**, e124 (2013).
40. Kramer, B. P., Fischer, C. & Fussenegger, M. BioLogic gates enable logical transcription control in mammalian cells. *Biotechnol. Bioeng.* **87**, 478–484 (2004).
41. Lohmueller, J. J., Armel, T. Z. & Silver, P. A. A tunable zinc finger-based framework for Boolean logic computation in mammalian cells. *Nucleic Acids Res.* **40**, 5180–5187 (2012).
42. Auslander, S., Auslander, D., Muller, M., Wieland, M. & Fussenegger, M. Programmable single-cell mammalian biocomputers. *Nature* **487**, 123–127 (2012).
43. Lienert, F. *et al.* Two- and three-input TALE-based AND logic computation in embryonic stem cells. *Nucleic Acids Res.* **41**, 9967–9975 (2013).
44. Burrill, D. R., Inniss, M. C., Boyle, P. M. & Silver, P. A. Synthetic memory circuits for tracking human cell fate. *Genes Dev.* **26**, 1486–1497 (2012).
45. Weber, W. *et al.* A synthetic time-delay circuit in mammalian cells and mice. *Proc. Natl Acad. Sci. USA* **104**, 2643–2648 (2007).
46. Tigges, M., Marquez-Lago, T. T., Stelling, J. & Fussenegger, M. A tunable synthetic mammalian oscillator. *Nature* **457**, 309–312 (2009).
47. Liang, J. C., Bloom, R. J. & Smolke, C. D. Engineering biological systems with synthetic RNA molecules. *Mol. Cell* **43**, 915–926 (2011).
48. Win, M. N. & Smolke, C. D. Higher-order cellular information processing with synthetic RNA devices. *Science* **322**, 456–460 (2008).
49. Culler, S. J., Hoff, K. G. & Smolke, C. D. Reprogramming cellular behavior with RNA controllers responsive to endogenous proteins. *Science* **330**, 1251–1255 (2010).
- Describes splicing-based RNA control devices that detect endogenous protein inputs in a combinatorial manner.**
50. Rinaudo, K. *et al.* A universal RNAi-based logic evaluator that operates in mammalian cells. *Nature Biotech.* **25**, 795–801 (2007).
51. Ellington, A. D. & Szostak, J. W. *In vitro* selection of RNA molecules that bind specific ligands. *Nature* **346**, 818–822 (1990).
52. Yen, H. C., Xu, Q., Chou, D. M., Zhao, Z. & Elledge, S. J. Global protein stability profiling in mammalian cells. *Science* **322**, 918–923 (2008).
53. Hershkó, A. & Ciechanover, A. The ubiquitin system. *Annu. Rev. Biochem.* **67**, 425–479 (1998).
54. Nishimura, K., Fukagawa, T., Takisawa, H., Kakimoto, T. & Kanemaki, M. An auxin-based degron system for the rapid depletion of proteins in nonplant cells. *Nature Methods* **6**, 917–922 (2009).
55. Bongor, K. M., Chen, L. C., Liu, C. W. & Wandless, T. J. Small-molecule displacement of a cryptic degron causes conditional protein degradation. *Nature Chem. Biol.* **7**, 531–537 (2011).
56. Banaszynski, L. A., Chen, L. C., Maynard-Smith, L. A., Ooi, A. G. & Wandless, T. J. A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. *Cell* **126**, 995–1004 (2006).
57. Renicke, C., Schuster, D., Usherenko, S., Essen, L. O. & Taxis, C. A. LOV2 domain-based optogenetic tool to control protein degradation and cellular function. *Chem. Biol.* **20**, 619–626 (2013).
58. Dong, S., Rogan, S. C. & Roth, B. L. Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLS. *Nature Protoc.* **5**, 561–573 (2010).
59. Struhl, G. & Adachi, A. Nuclear access and action of notch *in vivo*. *Cell* **93**, 649–660 (1998).
60. Barnea, G. *et al.* The genetic design of signaling cascades to record receptor activation. *Proc. Natl Acad. Sci. USA* **105**, 64–69 (2008).
61. Howard, P. L., Chia, M. C., Del Rizzo, S., Liu, F. F. & Pawson, T. Redirecting tyrosine kinase signaling to an apoptotic caspase pathway through chimeric adaptor proteins. *Proc. Natl Acad. Sci. USA* **100**, 11267–11272 (2003).
62. Lim, W. A. Designing customized cell signalling circuits. *Nature Rev. Mol. Cell Biol.* **11**, 393–403 (2010).
63. Kapp, G. T. *et al.* Control of protein signaling using a computationally designed GTPase/GEF orthogonal pair. *Proc. Natl Acad. Sci. USA* **109**, 5277–5282 (2012).
- Shows that the interaction domain of a GTPase and its activator can be reengineered to obtain a pair of orthogonal synthetic signalling proteins.**
64. Reinke, A. W., Grant, R. A. & Keating, A. E. A synthetic coiled-coil interactome provides heterospecific modules for molecular engineering. *J. Am. Chem. Soc.* **132**, 6025–6031 (2010).
65. Mootz, H. D., Blum, E. S., Tyszkiewicz, A. B. & Muir, T. W. Conditional protein splicing: a new tool to control protein structure and function *in vitro* and *in vivo*. *J. Am. Chem. Soc.* **125**, 10561–10569 (2003).
66. Berrade, L., Kwon, Y. & Camarero, J. A. Photomodulation of protein trans-splicing through backbone photocaging of the DnaE split intein. *ChemBiochem* **11**, 1368–1372 (2010).
67. Selgrade, D. F., Lohmueller, J. J., Lienert, F. & Silver, P. A. Protein scaffold-activated protein trans-splicing in mammalian cells. *J. Am. Chem. Soc.* **135**, 7713–7719 (2013).
68. Wend, S. *et al.* Optogenetic control of protein kinase activity in mammalian cells. *ACS Synth. Biol.* <http://dx.doi.org/10.1021/sb400090s> (2013).
69. Bugaj, L. J., Choksi, A. T., Mesuda, C. K., Kane, R. S. & Schaffer, D. V. Optogenetic protein clustering and signaling activation in mammalian cells. *Nature Methods* **10**, 249–252 (2013).
70. Garcia-Otin, A. L. & Guillouf, F. Mammalian genome targeting using site-specific recombinases. *Front. Biosci.* **11**, 1108–1136 (2006).
71. Taniguchi, H. *et al.* A resource of Cre driver lines for genetic targeting of GABAergic neurons in cerebral cortex. *Neuron* **71**, 995–1013 (2011).
72. Hirrlinger, J. *et al.* Split-cre complementation indicates coincident activity of different genes *in vivo*. *PLoS ONE* **4**, e4286 (2009).
73. Wang, P. *et al.* Intersectional Cre driver lines generated using split-intein mediated split-Cre reconstitution. *Sci. Rep.* **2**, 497 (2012).
74. Bibikova, M., Beumer, K., Trautman, J. K. & Carroll, D. Enhancing gene targeting with designed zinc finger nucleases. *Science* **300**, 764 (2003).
75. Porteus, M. H. & Baltimore, D. Chimeric nucleases stimulate gene targeting in human cells. *Science* **300**, 763 (2003).

76. Christian, M. *et al.* Targeting DNA double-strand breaks with TAL effector nucleases. *Genetics* **186**, 757–761 (2010).
77. Fu, Y. *et al.* High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. *Nature Biotech.* **31**, 822–826 (2013).
78. Wang, H. H. *et al.* Programming cells by multiplex genome engineering and accelerated evolution. *Nature* **460**, 894–898 (2009).
79. Rios, X. *et al.* Stable gene targeting in human cells using single-strand oligonucleotides with modified bases. *PLoS ONE* **7**, e36697 (2012).
80. Gibson, D. G., Smith, H. O., Hutchison, C. A., 3rd, Venter, J. C. & Merryman, C. Chemical synthesis of the mouse mitochondrial genome. *Nature Methods* **7**, 901–903 (2010).
81. Dymond, J. S. *et al.* Synthetic chromosome arms function in yeast and generate phenotypic diversity by design. *Nature* **477**, 471–476 (2011).
82. Schlabach, M. R., Hu, J. K., Li, M. & Elledge, S. J. Synthetic design of strong promoters. *Proc. Natl Acad. Sci. USA* **107**, 2538–2543 (2010).
83. Patwardhan, R. P. *et al.* High-resolution analysis of DNA regulatory elements by synthetic saturation mutagenesis. *Nature Biotech.* **27**, 1173–1175 (2009).
84. Kheradpour, P. *et al.* Systematic dissection of regulatory motifs in 2000 predicted human enhancers using a massively parallel reporter assay. *Genome Res.* **23**, 800–811 (2013).
85. Melnikov, A. *et al.* Systematic dissection and optimization of inducible enhancers in human cells using a massively parallel reporter assay. *Nature Biotech.* **30**, 271–277 (2012).
86. Patwardhan, R. P. *et al.* Massively parallel functional dissection of mammalian enhancers *in vivo*. *Nature Biotech.* **30**, 265–270 (2012).
87. Smith, R. P. *et al.* Massively parallel decoding of mammalian regulatory sequences supports a flexible organizational model. *Nature Genet.* **45**, 1021–1028 (2013).
- References 84–87 describe how massively parallel reporter assays can be used to study large libraries of synthetic variants of gene regulatory sequences.**
88. Xu, G. L. & Bestor, T. H. Cytosine methylation targeted to pre-determined sequences. *Nature Genet.* **17**, 376–378 (1997).
89. Maeder, M. L. *et al.* Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. *Nature Biotech.* **31**, 1137–1142 (2013).
90. Mendenhall, E. M. *et al.* Locus-specific editing of histone modifications at endogenous enhancers. *Nature Biotech.* **31**, 1133–1136 (2013).
91. Hathaway, N. A. *et al.* Dynamics and memory of heterochromatin in living cells. *Cell* **149**, 1447–1460 (2012).
- References 89–91 report the fusion of chromatin-modifying proteins to artificial DNA-binding factors, which can provide insight into how chromatin states are regulated.**
92. Cantone, I. *et al.* A yeast synthetic network for *in vivo* assessment of reverse-engineering and modeling approaches. *Cell* **137**, 172–181 (2009).
93. Kang, T. *et al.* Reverse engineering validation using a benchmark synthetic gene circuit in human cells. *ACS Synth. Biol.* **2**, 255–262 (2013).
94. Shen-Orr, S. S., Milo, R., Mangan, S. & Alon, U. Network motifs in the transcriptional regulation network of *Escherichia coli*. *Nature Genet.* **31**, 64–68 (2002).
95. Gerstein, M. B. *et al.* Architecture of the human regulatory network derived from ENCODE data. *Nature* **489**, 91–100 (2012).
96. Kramer, B. P. & Fussenegger, M. Hysteresis in a synthetic mammalian gene network. *Proc. Natl Acad. Sci. USA* **102**, 9517–9522 (2005).
97. Bleris, L. *et al.* Synthetic incoherent feedforward circuits show adaptation to the amount of their genetic template. *Mol. Syst. Biol.* **7**, 519 (2011).
98. Pomeroy, J. R., Kim, S. Y. & Ferrell, J. E. Jr. Systems-level dissection of the cell-cycle oscillator: bypassing positive feedback produces damped oscillations. *Cell* **122**, 565–578 (2005).
99. Riccione, K. A., Smith, R. P., Lee, A. J. & You, L. A synthetic biology approach to understanding cellular information processing. *ACS Synth. Biol.* **1**, 389–402 (2012).
100. James, J. R. & Vale, R. D. Biophysical mechanism of T-cell receptor triggering in a reconstituted system. *Nature* **487**, 64–69 (2012).
- Recapitulates T cell signalling by heterologous expression of more than 10 pathway-associated proteins in a non-immune cell.**
101. O'Shaughnessy, E. C., Palani, S., Collins, J. J. & Sarkar, A. C. Tunable signal processing in synthetic MAP kinase cascades. *Cell* **144**, 119–131 (2011).
102. Gaudet, D. *et al.* Efficacy and long-term safety of alipogene tiparvovect (AAV1-LPL⁵⁴⁴⁷) gene therapy for lipoprotein lipase deficiency: an open-label trial. *Gene Ther.* **20**, 361–369 (2013).
103. Dalkara, D. *et al.* *In vivo*-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. *Sci. Transl. Med.* **5**, 189ra76 (2013).
104. Aiuti, A. *et al.* Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott–Aldrich syndrome. *Science* **341**, 1233151 (2013).
105. Biffi, A. *et al.* Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. *Science* **341**, 1233158 (2013).
106. Perez, E. E. *et al.* Establishment of HIV-1 resistance in CD4⁺ T cells by genome editing using zinc-finger nucleases. *Nature Biotech.* **26**, 808–816 (2008).
107. Gross, G., Waks, T. & Eshhar, Z. Expression of immunoglobulin–T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. *Proc. Natl Acad. Sci. USA* **86**, 10024–10028 (1989).
- The development of CAR technology.**
108. Brentjens, R. J. *et al.* Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. *Blood* **118**, 4817–4828 (2011).
109. Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. *Nature Biotech.* **31**, 71–75 (2013).
110. Lanitis, E. Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity *in vivo*. *Cancer Immunol. Res.* <http://dx.doi.org/10.1158/2326-6066.CIR-13-0008> (2013).
111. Chen, Y. Y., Jensen, M. C. & Smolke, C. D. Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems. *Proc. Natl Acad. Sci. USA* **107**, 8531–8536 (2010).
112. Wei, P. K. Bacterial virulence proteins as tools to rewire kinase pathways in yeast and immune cells. *Nature* **488**, 384–388 (2012).
- Shows that amplitude and pause switch devices that are based on bacterial virulence proteins can be used to modulate immune response of T cells.**
113. Folcher, M. & Fussenegger, M. Synthetic biology advancing clinical applications. *Curr. Opin. Chem. Biol.* **16**, 345–354 (2012).
114. Lim, F. & Sun, A. M. Microencapsulated islets as bioartificial endocrine pancreas. *Science* **210**, 908–910 (1980).
115. Ye, H., Daoud-Ei Baba, M., Peng, R. W. & Fussenegger, M. A synthetic optogenetic transcription device enhances blood-glucose homeostasis in mice. *Science* **332**, 1565–1568 (2011).
116. Ortiz-Sanchez, E., Helguera, G., Daniels, T. R. & Penichet, M. L. Antibody-cytokine fusion proteins: applications in cancer therapy. *Expert Opin. Biol. Ther.* **8**, 609–632 (2008).
117. Byrne, H., Conroy, P. J., Whistock, J. C. & O'Kennedy, R. J. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. *Trends Biotechnol.* **31**, 621–632 (2013).
118. Cironi, P., Swinburne, I. A. & Silver, P. A. Enhancement of cell type specificity by quantitative modulation of a chimeric ligand. *J. Biol. Chem.* **283**, 8469–8476 (2008).
119. Taylor, N. D., Way, J. C., Silver, P. A. & Cironi, P. Anti-glycophorin single-chain Fv fusion to low-affinity mutant erythropoietin improves red blood cell-lineage specificity. *Protein Eng. Des. Sel.* **23**, 251–260 (2010).
120. Zephati, O. *et al.* Intracellular delivery of proteins with a new lipid-mediated delivery system. *J. Biol. Chem.* **276**, 35103–35110 (2001).
121. Akinc, A. *et al.* Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. *Mol. Ther.* **18**, 1357–1364 (2010).
122. Akinc, A. *et al.* A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. *Nature Biotech.* **26**, 561–569 (2008).
123. Kam, N. W., Liu, Z. & Dai, H. Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. *J. Am. Chem. Soc.* **127**, 12492–12493 (2005).
124. Hasadsri, L., Kreuter, J., Hattori, H., Iwasaki, T. & George, J. M. Functional protein delivery into neurons using polymeric nanoparticles. *J. Biol. Chem.* **284**, 6972–6981 (2009).
125. Lee, S. K., Han, M. S., Asokan, S. & Tung, C. H. Effective gene silencing by multilayered siRNA-coated gold nanoparticles. *Small* **7**, 364–370 (2011).
126. Nishina, K. *et al.* Efficient *in vivo* delivery of siRNA to the liver by conjugation of alpha-tocopherol. *Mol. Ther.* **16**, 734–740 (2008).
127. Rizk, S. S. *et al.* An engineered substance P variant for receptor-mediated delivery of synthetic antibodies into tumor cells. *Proc. Natl Acad. Sci. USA* **106**, 11011–11015 (2009).
128. Bidwell, G. L., 3rd & Raucher, D. Cell penetrating elastin-like polypeptides for therapeutic peptide delivery. *Adv. Drug Deliv. Rev.* **62**, 1486–1496 (2010).
129. Thompson, D. B., Cronican, J. J. & Liu, D. R. Engineering and identifying supercharged proteins for macromolecule delivery into mammalian cells. *Methods Enzymol.* **503**, 293–319 (2012).
130. Cronican, J. J. *et al.* A class of human proteins that deliver functional proteins into mammalian cells *in vitro* and *in vivo*. *Chem. Biol.* **18**, 833–838 (2011).
131. Dormitzer, P. R. *et al.* Synthetic generation of influenza vaccine viruses for rapid response to pandemics. *Sci. Transl. Med.* **5**, 185ra68 (2013).
132. Coleman, J. R. *et al.* Virus attenuation by genome-scale changes in codon pair bias. *Science* **320**, 1784–1787 (2008).
133. Mueller, S. *et al.* Live attenuated influenza virus vaccines by computer-aided rational design. *Nature Biotech.* **28**, 723–726 (2010).
134. Geall, A. J., Mandl, C. W. & Ulmer, J. B. RNA: The new revolution in nucleic acid vaccines. *Semin. Immunol.* **25**, 152–159 (2013).
135. Boudreau, J. E., Bonehill, A., Thielemans, K. & Wan, Y. Engineering dendritic cells to enhance cancer immunotherapy. *Mol. Ther.* **19**, 841–853 (2011).
136. Huh, D. *et al.* A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. *Sci. Transl. Med.* **4**, 159ra147 (2012).
137. Greber, D. & Fussenegger, M. An engineered mammalian band-pass network. *Nucleic Acids Res.* **38**, e174 (2010).
138. Galloway, K. E., Franco, E. & Smolke, C. D. Dynamically reshaping signaling networks to program cell fate via genetic controllers. *Science* **341**, 1235005 (2013).
139. Nissim, L. & Bar-Ziv, R. H. A tunable dual-promoter integrator for targeting of cancer cells. *Mol. Syst. Biol.* **6**, 444 (2010).
140. Papapetrou, E. P. *et al.* Genomic safe harbors permit high β -globin transgene expression in thalassemia induced pluripotent stem cells. *Nature Biotech.* **29**, 73–78 (2011).
141. Themeli, M. *et al.* Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. *Nature Biotech.* **31**, 928–933 (2013).
142. Carr, P. A. & Church, G. M. Genome engineering. *Nature Biotech.* **27**, 1151–1162 (2009).
143. Gibson, D. G. *et al.* Enzymatic assembly of DNA molecules up to several hundred kilobases. *Nature Methods* **6**, 343–345 (2009).
144. Guye, P., Li, Y., Wroblewska, L., Duportet, X. & Weiss, R. Rapid, modular and reliable construction of complex mammalian gene circuits. *Nucleic Acids Res.* **41**, e156 (2013).
145. Torella, J. P. *et al.* Rapid construction of insulated genetic circuits via synthetic sequence-guided isothermal assembly. *Nucleic Acids Res.* <http://dx.doi.org/10.1093/nar/gkt860> (2013).
146. Pathak, G. P., Vrana, J. D. & Tucker, C. L. Optogenetic control of cell function using engineered photoreceptors. *Biol. Cell* **105**, 59–72 (2013).

Acknowledgements

The authors apologize to their colleagues whose work could not be cited owing to space limitations. They thank M. Inniss, J. Torella, T. Ford and J. Chen for helpful comments on the manuscript. The work in the author's laboratory was supported by a European Molecular Biology Organization Fellowship and a Human Frontier Science Program Fellowship to F.L.; a Swiss National Science Foundation Fellowship to A.G.; and funds from NIH and the Defense Advanced Research Projects Agency to P.A.S.

SUPPLEMENTARY INFORMATION

See online article: S1 (table)

ALL LINKS ARE ACTIVE IN THE ONLINE PDF

Copyright of Nature Reviews Molecular Cell Biology is the property of Nature Publishing Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.